Perspective Therapeutics, Inc.

AMEX:CATX

Medical - Devices

Healthcare
$0.78 +0.50%

+$0.02 today

Market cap
$94.20M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$107.27
52W Low $1.96High $6.16

Volume 2.69M

Average 1.44M

CATX Pre-Tax Margin

Income before tax as a percentage of revenue.

Perspective Therapeutics, Inc.AMEX: CATX

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -34459.2%

Pre-tax margin was -34459.2% in Q1 FY2026, down 29144.3 pp from a year earlier. On a trailing-twelve-month basis it was -18194.2%, down 12290.7 pp year over year. Over 3 fiscal years it narrowed by 11606.6 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-34459.2%+54571.0 pp QoQ
Last fiscal yearDec 2025
-11813.1%-6216.4 pp YoY
LTMMar 2026
-18194.2%-12290.7 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-29144.3 pp——
1 year-6216.4 pp——
3 years-11606.6 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-11813.1%
Year-over-year change
-6216.4pp

Pre-Tax Margin vs competitors

How CATX compares with its peers on the latest reported figures

  • CATX's LTM Mar 2026 pre-tax margin of -18194.2% is the lowest of the 5 companies compared; the peer median is -38.3%.
  • Its year-over-year change of -12290.7 pp is the lowest of 5, against a peer median of +9.4 pp.
  • Over three fiscal years its change of -11606.6 pp compares with a peer median of +144.0 pp.
CATX Competitors Peer median
Pre-Tax Margin for CATX and competitors
Company Period LTM level YoY 3-year change
DCTHDelcath Systems, Inc.LTM Mar 20261.5% +27.5 pp+1346.8 pp
NVCRNovoCure LimitedLTM Mar 2026-26.0% -5.1 pp-5.6 pp
SRTSSensus Healthcare, Inc.LTM Mar 2026-50.6% -59.3 pp-97.9 pp
TLSITriSalus Life Sciences, Inc.LTM Mar 2026-60.8% +23.8 pp+293.7 pp
CATXPerspective Therapeutics, Inc.LTM Mar 2026-18194.2% -12290.7 pp-11606.6 pp
Peer median (excluding CATX) -38.3%+9.4 pp+144.0 pp

Competitors are the stored peer set for CATX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2022
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.8M7.1M1.43M1.45M884K
Cost of Revenue6.18M5.47M000
Gross Profit4.62M1.63M1.43M(852K)(2.37M)
Gross Margin42.8%23.0%100.0%-58.6%-267.8%
Research & Development2.58M2.6M21.31M41.64M84.22M
Selling, General & Admin9.43M14.21M21.06M26.61M30.23M
Operating Expenses12.01M17.43M42.38M92.34M113.56M
Depreciation & Amortization248K344K981K2.31M3.25M
EBITDA(7.39M)(14.84M)(39.96M)10.46M(100.8M)
EBITDA Margin-68.5%-208.9%-2786.6%719.3%-11402.8%
Operating Income(7.39M)(15.18M)(40.94M)10.46M(113.56M)
Operating Margin-68.5%-213.7%-2855.0%719.3%-12846.6%
Interest Income119K1.12M934K10.52M8.11M
Interest Expense119K084K(48K)376K
Other Income / Expenses119K512K835K(91.84M)9.14M
Income Before Tax(7.27M)(14.67M)(40.11M)(81.38M)(104.43M)
Pre-Tax Margin-67.4%-206.5%-2796.8%-5596.7%-11813.1%
Income Tax Expense(119K)0(2.65M)(2.1M)(793K)
Net Income(7.15M)(14.67M)(46.51M)(79.28M)(103.12M)
Net Margin-66.3%-206.5%-3243.2%-5452.5%-11665.3%
EPS (Basic)(0.13)(0.27)(0.85)(1.23)(1.40)
EPS (Diluted)(0.13)(0.27)(0.85)(1.23)(1.40)
Weighted Avg Shares54.91M54.91M54.91M64.43M73.81M
Weighted Avg Shares (Diluted)54.91M54.91M54.91M64.43M73.81M

Perspective Therapeutics, Inc.

AMEX:CATX

Intrinsic Alpha fair value

Locked

Current Price

$0.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.